Navneet Majhail
Overview
Explore the profile of Navneet Majhail including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
875
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Battiwalla M, Chao J, Cox T, Cruz J, Donnellan W, Eghtedar A, et al.
Clin Hematol Int
. 2024 Oct;
6(4):43-52.
PMID: 39417014
The treatment setting influences acute myeloid leukemia (AML) outcomes. Most cancer patients receive care in the community, yet few studies have evaluated the effectiveness of clinical programs outside of academic...
2.
Aldoss I, Roloff G, Faramand R, Kopmar N, Lin C, Advani A, et al.
Blood Adv
. 2024 Aug;
8(23):6139-6147.
PMID: 39093952
The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189...
3.
Metheny L, Sobecks R, Cho C, Fu P, Margevicius S, Wang J, et al.
Blood Adv
. 2024 Jan;
8(6):1384-1391.
PMID: 38170741
The curative potential of allogeneic hematopoietic transplantation (allo-HCT) in patients with acute lymphoblastic leukemia (ALL) is hampered by relapse. Inotuzumab ozogamicin (INO) is an anti-CD22 monoclonal antibody bound to calicheamicin,...
4.
Pardeep A, Bhattacharjee U, Sharma R, De R, Singh C, Kaundal S, et al.
Blood Cell Ther
. 2023 Dec;
6(4):124-128.
PMID: 38149023
Introduction: While there are data about return to work after hematopoietic cell transplantation (HCT) in survivors from resource-rich regions, similar data from resource-challenged settings are scarce. This study assessed the...
5.
Kanate A, Majhail N, DeFilipp Z, Dhakal B, Dholaria B, Hamilton B, et al.
Transplant Cell Ther
. 2023 Jul;
29(10):594-597.
PMID: 37422194
The American Society for Transplantation and Cellular Therapy (ASTCT) published its guidelines on indications for autologous and allogeneic hematopoietic cell transplantation (HCT) and immune effector cell therapy (IECT) in 2020....
6.
Maakaron J, Zhang M, Chen K, Abhyankar S, Bhatt V, Chhabra S, et al.
Bone Marrow Transplant
. 2022 Apr;
57(6):911-917.
PMID: 35368040
Acute Myeloid Leukemia (AML) has a median age at diagnosis of 67 years. The most common curative therapy remains an allogeneic hematopoietic stem cell transplantation (HCT), yet it is complicated...
7.
ODonnell P, Brunstein C, Fuchs E, Zhang M, Allbee-Johnson M, Antin J, et al.
Transplant Cell Ther
. 2021 Nov;
28(2):109.e1-109.e8.
PMID: 34775146
Randomized clinical trials offer the highest-quality data for modifying clinical practice. Results of a phase III randomized trial of nonmyeloablative transplantation for adults with high-risk hematologic malignancies with 2 umbilical...
8.
Kharfan-Dabaja M, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al.
Transplant Cell Ther
. 2021 Jul;
27(8):642-649.
PMID: 34304802
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications for transplantation, availability of...
9.
Reddy P, Davies S, Majhail N, Sandmaier B, Hari P, Cutler C
Blood Adv
. 2020 Nov;
4(21):5431-5432.
PMID: 33152057
No abstract available.
10.
Dholaria B, Savani B, Hamilton B, Oran B, Liu H, Tallman M, et al.
Transplant Cell Ther
. 2020 Sep;
27(1):6-20.
PMID: 32966881
The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert...